The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chronic pain, epilepsy, and inflammatory conditions.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

As patients increasingly turn to cannabis for chronic pain, clinicians grapple with mixed evidence and a lack of high-quality ...

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB ...

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Exhale Wellness launches its new line of Delta 9 Gummies - Bottle Caps. Learn about the product - ingredients, flavors, lab ...

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

The 9 Most Dangerous Foods for Dogs—And the Ones You Can Safely Swap In first appeared on Parade Pets on Jul 6, 2025 This ...

It interacts primarily with CB1 receptors, affecting mood, memory and appetite. CBD is a major non-psychoactive cannabinoid that may affect anxiety, pain and inflammation and reduce seizures.

The study found that youth who vaped cannabis experienced more mental-health symptoms than those who smoked dry herbs and ...

Teen vaping habits are shifting toward stronger and more mysterious substances. Synthetic cannabinoids are rising fast — and ...